MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26020834 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Wiktoria Bębenek und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland. Hauptthemen laut MEDLINE: Phthalazines, Piperazines, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Centre, Poland.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) cells critically depend on PARP1 and CHK1 activation for survival. Combining the PARP inhibitor (PARPi) olaparib with a CHK1 inhibitor (MK-8776, CHK1i) produced a synergistic effect, reducing cell viability and inducing marked oxidative stress and DNA damage, particularly in the HepG2 cells. This dual treatment significantly increased apoptosis markers, including γH2AX and caspase-3/7 activity. Both HCC cell lines exhibited heightened sensitivity to the combined treatment. The effect of drugs on the expression of proliferation markers in an olaparib-resistant patient-derived xenograft (PDX) model of ovarian cancer was also investigated. Ovarian tumors displayed reduced tissue growth, as reflected by a drop in proliferation marker Ki-67 levels in response to PARPi combined with CHK1i. No changes were observed in corresponding liver tissues using Ki-67 and pCHK staining, which indicates the absence of metastases and a hepatotoxic effect. Thus, our results indicate that the dual inhibition of PARP and CHK1 may prove to be a promising therapeutic approach in the treatment of primary HCC as well as OC tumors without the risk of liver metastases, especially in patients with olaparib-resistant tumor profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.
- Doctoral School of Exact and Natural Sciences, University of Lodz, Jana Matejki 21/23, 90-237 Lodz, Poland.
- Faculty of Science, University of Jan Evangelista Purkyně in Ústí nad Labem, 400 96 Ustí nad Labem, Czech Republic.
- Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland.
- Department of Experimental Immunology, Maria Sklodowska-Curie National Research Institute of Oncology, 5 Roentgena Street, 02-781 Warsaw, Poland.
- Department of Cytobiochemistry, Institute of Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland.
ORCID-Profile: Wiktoria Bębenek, Arkadiusz Gajek, Agnieszka Marczak, Magdalena Bryś, Aneta Rogalska
Förderung
- National Science Centre, Poland
Zitieren
APA
Bębenek, W., Gajek, A., Marczak, A., Malý, J., Smejkal, J., Statkiewicz, M., Rusetska, N., Bryś, M., & Rogalska, A. (2025). MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26020834
Vancouver
Bębenek W, Gajek A, Marczak A, Malý J, Smejkal J, Statkiewicz M, et al. MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26020834
BibTeX
@article{Bbenek2025,
author = {Bębenek, Wiktoria and Gajek, Arkadiusz and Marczak, Agnieszka and Malý, Jan and Smejkal, Jiří and Statkiewicz, Małgorzata and Rusetska, Natalia and Bryś, Magdalena and Rogalska, Aneta},
title = {MK-8776 and Olaparib Combination Acts Synergistically in Hepatocellular Carcinoma Cells, Demonstrating Lack of Adverse Effects on Liver Tissues in Ovarian Cancer PDX Model},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26020834}
}
EUVIMED